{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T09:30:16Z","timestamp":1780824616689,"version":"3.54.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T00:00:00Z","timestamp":1623715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Geneva Center for Emerging Viral Diseases and the Division of Humanitarian and Tropical Medicine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and rationale<\/jats:title>\n                  <jats:p>Geneva University Hospitals were granted a temporary authorization to administer the recombinant live vesicular stomatitis virus rVSV-ZEBOV (Ervebo\u00ae) vaccine to expatriate humanitarian frontline workers (FLWs) prior to mission deployment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Our aims were to assess the feasibility of FLW vaccination before deployment and to report adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>FLWs received a single injection of rVSV-ZEBOV (&amp;gt;7.2E7 plaque forming unit) during their pre-deployment medical check-up at the Travel Medicine Clinic of the Geneva University Hospitals (Day 0). A safety questionnaire regarding potential AEs was emailed to FLWs on Days 3 and 21. Early and delayed AEs were those starting within 3 or 21 days of vaccination, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Between 1 August 2019 and 30 June 2020, 124 FLWs received the rVSV-ZEBOV vaccine. Eighty-six volunteers (86\/124; 69%) received a concomitant vaccine. The response rate to the follow-up questionnaire was 88 and 55% at Days 3 and 21, respectively. Most respondents (105\/109; 96.3%), experienced at least one AE, with a mean of three (\u00b1SD 1.75) AEs per person. The most common AE was injection site pain, followed by fever (53\/109; 48.6%), fatigue (51\/109; 46.7%) and myalgia (49\/109; 44.9%). Most early AEs (360\/377; 95.4%) resolved within 3 days, reflecting vaccine reactogenicity. Delayed AEs were reported by 6\/69 (7.2%) subjects, the median time to symptom onset was 11 days (range: 5\u201314); half of them were joint-related AEs (3\/6). Four serious adverse events (SAE) were observed: two cases of high grade fever, one rash and one case of arthritis. Two suspected unexpected serious adverse reactions were observed: one case of continuing recurrent transient dizziness and fatigue considered related to the vaccine; and one case of presbyopia that was deemed unrelated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>AEs to rVSV-ZEBOV were common but in general transient and were well tolerated, pre-deployment rVSV-ZEBOV vaccination in FLW is feasible and can be included with pre-mission check-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jtm\/taab086","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T19:12:28Z","timestamp":1623093148000},"source":"Crossref","is-referenced-by-count":9,"title":["Feasibility and safety of rVSV-ZEBOV vaccination of humanitarian health workers against Ebola virus disease: an observational study"],"prefix":"10.1093","volume":"28","author":[{"given":"Luisa","family":"Carnino","sequence":"first","affiliation":[{"name":"Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"},{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-5069","authenticated-orcid":false,"given":"Pauline","family":"Vetter","sequence":"additional","affiliation":[{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"},{"name":"Geneva Center for Emerging Viral Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland"},{"name":"Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Peyraud","sequence":"additional","affiliation":[{"name":"M\u00e9decins Sans Fronti\u00e8res, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigiriya","family":"Aebischer-Perone","sequence":"additional","affiliation":[{"name":"Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"},{"name":"Health Unit, International Committee of the Red Cross (ICRC), Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Chappuis","sequence":"additional","affiliation":[{"name":"Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"},{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Huttner","sequence":"additional","affiliation":[{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"},{"name":"Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"},{"name":"Center for Vaccinology, University and University Hospitals of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Kaiser","sequence":"additional","affiliation":[{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"},{"name":"Geneva Center for Emerging Viral Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, Geneva 1205, Switzerland"},{"name":"Division of Infectious Diseases, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3371-4320","authenticated-orcid":false,"given":"Gilles","family":"Eperon","sequence":"additional","affiliation":[{"name":"Division of Tropical and Humanitarian Medicine, Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 6, Geneva 1205, Switzerland"},{"name":"University of Geneva, Rue Michel-Servet 1, Geneva 1205, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,6,15]]},"reference":[{"key":"2021122911112490900_ref1","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1016\/S1473-3099(15)00154-1","article-title":"The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase 1\/2 trial","volume":"15","author":"Huttner","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2021122911112490900_ref2","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"2021122911112490900_ref3","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1056\/NEJMoa1502924","article-title":"Phase 1 trials of rVSV Ebola vaccine in Africa and Europe","volume":"374","author":"Agnandji","year":"2016","journal-title":"N Engl J Med"},{"key":"2021122911112490900_ref4","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/S0140-6736(15)61117-5","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial","volume":"386","author":"Henao-Restrepo","year":"2015","journal-title":"Lancet"},{"key":"2021122911112490900_ref5","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1126\/science.aaa4919","article-title":"An Ebola whole-virus vaccine is protective in nonhuman primates","volume":"348","author":"Marzi","year":"2015","journal-title":"Science"},{"key":"2021122911112490900_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/tay152","article-title":"Ebola vaccines: ready to use for humanitarian health workers","volume":"26","author":"Genton","year":"2019","journal-title":"J Travel Med"},{"key":"2021122911112490900_ref7","doi-asserted-by":"publisher","first-page":"7171","DOI":"10.1016\/j.vaccine.2018.09.009","article-title":"Safety of the rVSV ZEBOV vaccine against Ebola Zaire among frontline workers in Guinea","volume":"37","author":"Juan-Giner","year":"2019","journal-title":"Vaccine"},{"key":"2021122911112490900_ref8","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1080\/14760584.2018.1546582","article-title":"Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?","volume":"17","author":"Huttner","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"2021122911112490900_ref9","author":"FDA. ERVEBO"},{"key":"2021122911112490900_ref10","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/nm.4201","article-title":"Human antibody repertoire after VSV-Ebola vaccination identifies novel targets and virus-neutralizing IgM antibodies","volume":"22","author":"Khurana","year":"2016","journal-title":"Nat Med"},{"key":"2021122911112490900_ref11","volume-title":"Preliminary Results on the Efficacy of rVSV-ZEBOV-GP Ebola Vaccine Using the Ring Vaccination Strategy in the Control of an Ebola Outbreak in the Democratic Republic of the Congo: An Example of Integration of Research into Epidemic Response"},{"key":"2021122911112490900_ref12","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of Ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Travel Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jtm\/advance-article-pdf\/doi\/10.1093\/jtm\/taab086\/38625281\/taab086.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/8\/taab086\/41959264\/taab086.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jtm\/article-pdf\/28\/8\/taab086\/41959264\/taab086.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,29]],"date-time":"2021-12-29T12:45:22Z","timestamp":1640781922000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jtm\/article\/doi\/10.1093\/jtm\/taab086\/6299197"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,15]]},"references-count":12,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,6,15]]},"published-print":{"date-parts":[[2021,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/jtm\/taab086","relation":{},"ISSN":["1195-1982","1708-8305"],"issn-type":[{"value":"1195-1982","type":"print"},{"value":"1708-8305","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,12]]},"published":{"date-parts":[[2021,6,15]]},"article-number":"taab086"}}